Sentiment-Signal
20,3
Stark Bearisch
Composite Score (0–100)
Insider (25%)
0
Keine Insider-Käufe
Institutionell (22,5%)
0
Keine neuen Positionen
Aktivist (12,5%)
0
Kein 13D/13G
Risikofreier Zins (T-Bills): 3,70% (Stand: 31.03.2026)
Score-Verlauf (90 Tage)
Kritische 8-K Meldungen
| Datum | Meldung | Schwere | Filing | Auszug |
|---|---|---|---|---|
| 12.06.2025 | Item 5.02 — Abgang Schlüsselpersonen | HOCH | SEC | Item 5.02. Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; C |
| 04.09.2024 | Item 5.02 — Abgang Schlüsselpersonen | HOCH | SEC | Item 5.02. Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; C |
| 15.07.2024 | Item 5.02 — Abgang Schlüsselpersonen | HOCH | SEC | incorporated herein by reference. Item 5.02. Departure of Directors or Certain Officers; Election of Directors; Appoin |
| 27.03.2023 | Item 5.02 — Abgang Schlüsselpersonen | HOCH | SEC | ecurities Act of 1933, as amended. Item 5.02. Departure of Directors or Certain Officers; Election of Directors; Appoi |
Stammdaten
Milestone Pharmaceuticals Inc., a biopharmaceutical company, focuses on the development and commercialization of cardiovascular medicines. The company is developing etripamil, a novel channel blocker, which is in Phase III clinical trial for the treatment of paroxysmal supraventricular tachycardia in the United States and Canada; and Phase II clinical trial for the treatment of atrial fibrillation and rapid ventricular rate. It has a license and collaboration agreement with Ji Xing Pharmaceuticals to develop and commercialize etripamil prophylactic and therapeutic uses in humans. The company was incorporated in 2003 and is headquartered in Montréal, Canada.
Unternehmen & Branche
| Name | Milestone Pharmaceuticals Inc. |
|---|---|
| Ticker | MIST |
| CIK | 0001408443 |
| Boerse | US |
| Sektor | Healthcare |
| Industrie | Biotechnology |
| SIC | 2834 · Pharmaceutical Preparations |
Wertpapier & Kennzahlen
| CUSIP | – |
|---|---|
| ISIN | – |
| Typ | Common Stock |
| Marktkapitalisierung | 155,5 Mio. USD |
| Beta | 0,69 |
| Dividendenrendite | 0,00 % |
Externe Quellen: SEC EDGAR » · FMP-Profil » · Yahoo Finance »
Finanzkennzahlen (SEC XBRL)
| Periode | Filing | Umsatz | Nettoergebnis | EPS | Aktiva | Eigenkapital |
|---|---|---|---|---|---|---|
| 2025-12-31 | 10-K | -63,058,000 | -0.75 | 113,561,000 | 41,769,000 | |
| 2025-09-30 | 10-Q | -11,922,000 | -0.12 | 87,750,000 | 20,501,000 | |
| 2025-06-30 | 10-Q | -12,966,000 | -0.20 | 47,417,000 | -17,745,000 | |
| 2025-03-31 | 10-Q | -20,761,000 | -0.31 | 61,885,000 | -6,123,000 | |
| 2024-12-31 | 10-K | -41,519,000 | -0.67 | 75,499,000 | 13,147,000 | |
| 2024-09-30 | 10-Q | -9,439,000 | -0.14 | 82,706,000 | 24,012,000 | |
| 2024-06-30 | 10-Q | -9,363,000 | -0.14 | 89,232,000 | 31,978,000 | |
| 2024-03-31 | 10-Q | -10,354,000 | -0.21 | 96,001,000 | 39,921,000 | |
| 2023-12-31 | 10-K | -59,685,000 | -1.39 | 75,226,000 | 16,771,000 | |
| 2023-09-30 | 10-Q | -15,081,000 | -0.35 | 87,116,000 | 28,504,000 | |
| 2023-06-30 | 10-Q | -16,043,000 | -0.37 | 97,019,000 | 40,408,000 | |
| 2023-03-31 | 10-Q | -14,950,000 | -0.35 | 111,080,000 | 53,935,000 | |
| 2022-12-31 | 10-K | -58,388,000 | -1.38 | 74,483,000 | 66,348,000 | |
| 2022-09-30 | 10-Q | -14,556,000 | -0.34 | 85,769,000 | 77,155,000 | |
| 2022-06-30 | 10-Q | -16,648,000 | -0.39 | 91,299,000 | 86,659,000 | |
| 2022-03-31 | 10-Q | -14,007,000 | -0.33 | 105,799,000 | 100,756,000 | |
| 2021-12-31 | 10-K | -42,853,000 | -1.02 | 119,849,000 | 112,600,000 | |
| 2021-09-30 | 10-Q | -14,225,000 | -0.34 | 133,776,000 | 127,417,000 | |
| 2021-06-30 | 10-Q | 770,000 | 0.02 | 145,495,000 | 139,594,000 | |
| 2021-03-31 | 10-Q | -12,514,000 | -0.30 | 138,443,000 | 131,992,000 |
Fondsaktivität (Vorquartalsvergleich)
Keine Fondsdaten für dieses Unternehmen vorhanden.
Insider-Transaktionen (12 Monate)
| Datum | Insider | Rolle | Typ | Stückzahl | Kurs | Wert (USD) | Δ | Trend |
|---|---|---|---|---|---|---|---|---|
| 2026-04-16 | Oliveto Joseph | Director, Officer, President and CEO | Open Market Sale | -36,500 | 2.26 | -82,490.00 | -91,2% | |
| 2026-01-26 | Bharucha David | Officer, Chief Medical Officer | Open Market Sale | -12,245 | 1.93 | -23,632.85 | -26,1% | |
| 2026-01-26 | Nelson Jeffrey Edward | Officer, Chief Operating Officer | Open Market Sale | -12,245 | 1.93 | -23,632.85 | -26,1% | |
| 2026-01-26 | Muller Lorenz | Officer, Chief Commercial Officer | Open Market Sale | -11,180 | 1.93 | -21,577.40 | -23,8% | |
| 2026-01-26 | Hasija Amit | Officer, CFO & EVP of Corp. Development | Open Market Sale | -12,245 | 1.93 | -23,632.85 | -26,1% | |
| 2026-01-26 | Oliveto Joseph | Director, Officer, President and CEO | Open Market Sale | -34,523 | 1.93 | -66,629.39 | -73,6% | |
| 2026-01-08 | Oliveto Joseph | Director, Officer, President and CEO | Open Market Sale | -43,000 | 2.25 | -96,750.00 | -106,9% | |
| 2026-01-07 | Oliveto Joseph | Director, Officer, President and CEO | Open Market Sale | -500 | 2.25 | -1,125.00 | -1,2% | |
| 2025-12-15 | Nelson Jeffrey Edward | Officer, Chief Operating Officer | Open Market Sale | -58,007 | 2.32 | -134,576.24 | -148,7% | |
| 2025-12-15 | Muller Lorenz | Officer, Chief Commercial Officer | Open Market Sale | -53,566 | 2.32 | -124,273.12 | -137,4% | |
| 2025-12-15 | Hasija Amit | Officer, CFO & EVP of Corp. Development | Open Market Sale | -58,007 | 2.32 | -134,576.24 | -148,7% | |
| 2025-12-15 | Oliveto Joseph | Director, Officer, President and CEO | Open Market Sale | -133,054 | 2.32 | -308,685.28 | -341,2% | |
| 2025-12-15 | Bharucha David | Officer, Chief Medical Officer | Open Market Sale | -58,007 | 2.32 | -134,576.24 | -148,7% |
Top-Fondshalter
Keine Fondsdaten zu dieser Aktie vorhanden.